Evidence map›Paper›PMID 38909137›Full record

ArticleBritish journal of cancer2024

Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms.

Hege Elvebakken, Andreas Venizelos, Aurel Perren, Anne Couvelard, Inger Marie B Lothe, Geir O Hjortland, Tor Å Myklebust, Johanna Svensson, Herish Garresori, Christian Kersten and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hege ElvebakkenDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway. Hege.Elvebakken@helse-mr.no.ORCID http://orcid.org/0000-0001-7458-4836
Andreas VenizelosK.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway.
Aurel PerrenInstitute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.ORCID http://orcid.org/0000-0002-6819-6092
Anne CouvelardDepartment of Pathology, Université Paris Cité and AP-HP, Bichat Hospital, Paris, France.
Inger Marie B LotheDepartment of Pathology, Oslo University Hospital, Oslo, Norway.
Geir O HjortlandDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Tor Å MyklebustDepartment of Research and Innovation, Møre and Romsdal Hospital Trust, Ålesund, Norway.ORCID http://orcid.org/0000-0003-4645-1635
Johanna SvenssonDepartment of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Herish GarresoriDepartment of Oncology, Stavanger University Hospital, Stavanger, Norway.
Christian KerstenDepartment of Research, Hospital of Southern Norway, Kristiansand, Norway.
Eva HofsliDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
Sönke DetlefsenDepartment of Pathology, Odense University Hospital, Odense, Denmark.
Lene W VestermarkDanish Medicines Agency, Copenhagen, Denmark.
Stian KnappskogK.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway.ORCID http://orcid.org/0000-0002-4153-1655
Halfdan SorbyeDepartment of Oncology, Haukeland University Hospital, Bergen, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChemotherapy has limited efficacy in advanced digestive high-grade neuroendocrine neoplasms (HG-NEN) and prognosis is dismal. Predictive markers for palliative chemotherapy are lacking, and prognostic markers are limited.

methodsDigestive HG-NEN patients (n = 229) were prospectively included 2013-2017. Pathological re-assessment revealed 188 neuroendocrine carcinomas (NEC) and 41 neuroendocrine tumours (NET G3). Tumour-DNA was sequenced across 360 cancer-related genes, assessing mutations (mut) and copy number alterations. We linked sequencing results to clinical information and explored potential markers for first-line chemotherapy efficacy and survival.

resultsIn NEC given cis/carboplatin and etoposide (PE), TP53mut predicted inferior response rate in multivariate analyses (p = 0.009) and no BRAFmut NEC showed response. In overall assessment of PE-treated NEC, no genetic alterations were prognostic for OS. For small-cell NEC, TP53mut were associated with longer OS (p = 0.011) and RB1 deletions predicted lack of immediate-progression (p = 0.003). In non-small cell NEC, APC mut were associated with immediate-progression and shorter PFS (p = 0.008/p = 0.004). For NET G3, ATRXmut, ARID1A- and ERS1 deletions were associated with shorter PFS.

conclusionCorrelations between genetic alterations and response/immediate-progression to PE were frequent in NEC but affected PFS or OS only when subdividing for cell-type. The classification of digestive NEC into large- and small-cell seems therefore molecularly and clinically relevant.

Indexed as

MutationNeuroendocrine TumorsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, NeuroendocrineDNA Copy Number VariationsEtoposideFemaleHumansMaleMiddle AgedNeoplasm GradingPrognosisCarboplatinEtoposideTumor Suppressor Protein p53

Identifiers

PMID38909137
PMCPMC11333587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.